MA55890A - Modulateurs de thr-beta et leurs procédés d'utilisation - Google Patents

Modulateurs de thr-beta et leurs procédés d'utilisation

Info

Publication number
MA55890A
MA55890A MA055890A MA55890A MA55890A MA 55890 A MA55890 A MA 55890A MA 055890 A MA055890 A MA 055890A MA 55890 A MA55890 A MA 55890A MA 55890 A MA55890 A MA 55890A
Authority
MA
Morocco
Prior art keywords
thr
methods
beta modulators
modulators
beta
Prior art date
Application number
MA055890A
Other languages
English (en)
Other versions
MA55890B1 (fr
Inventor
Jerome Deval
David Mcgowan
Pierre Jean-Marie Bernard Raboisson
Koen Vandyck
Original Assignee
Aligos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aligos Therapeutics Inc filed Critical Aligos Therapeutics Inc
Publication of MA55890A publication Critical patent/MA55890A/fr
Publication of MA55890B1 publication Critical patent/MA55890B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
MA55890A 2019-05-08 2020-05-07 Modulateurs de thr-beta avec un groupe de tête dioxo-1,2,4-triazyl MA55890B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962845252P 2019-05-08 2019-05-08
US201962944052P 2019-12-05 2019-12-05
US202063005661P 2020-04-06 2020-04-06
PCT/US2020/031904 WO2020227549A1 (fr) 2019-05-08 2020-05-07 MODULATEURS DE THR-β ET LEURS PROCÉDÉS D'UTILISATION
EP20729390.3A EP3965884B1 (fr) 2019-05-08 2020-05-07 Modulateurs de thr-beta avec un groupe de tête dioxo-1,2,4-triazyl

Publications (2)

Publication Number Publication Date
MA55890A true MA55890A (fr) 2022-03-16
MA55890B1 MA55890B1 (fr) 2025-03-28

Family

ID=70919081

Family Applications (1)

Application Number Title Priority Date Filing Date
MA55890A MA55890B1 (fr) 2019-05-08 2020-05-07 Modulateurs de thr-beta avec un groupe de tête dioxo-1,2,4-triazyl

Country Status (32)

Country Link
US (3) US11091467B2 (fr)
EP (2) EP3965884B1 (fr)
JP (2) JP7574223B2 (fr)
KR (1) KR20220017917A (fr)
CN (1) CN114096531B (fr)
AU (1) AU2020267576B2 (fr)
BR (1) BR112021021718A2 (fr)
CA (1) CA3139101A1 (fr)
CL (1) CL2021002883A1 (fr)
CO (1) CO2021015698A2 (fr)
DK (1) DK3965884T3 (fr)
ES (1) ES3020290T3 (fr)
FI (1) FI3965884T3 (fr)
GE (2) GEP20247637B (fr)
HR (1) HRP20250384T1 (fr)
HU (1) HUE070650T2 (fr)
IL (1) IL287720A (fr)
LT (1) LT3965884T (fr)
MA (1) MA55890B1 (fr)
MD (1) MD3965884T2 (fr)
MX (1) MX2021013472A (fr)
MY (1) MY210357A (fr)
PE (1) PE20220255A1 (fr)
PH (1) PH12021552782A1 (fr)
PL (1) PL3965884T3 (fr)
PT (1) PT3965884T (fr)
RS (1) RS66686B1 (fr)
SG (1) SG11202111552YA (fr)
SI (1) SI3965884T1 (fr)
TW (1) TWI855068B (fr)
WO (1) WO2020227549A1 (fr)
ZA (1) ZA202409114B (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
KR20220017917A (ko) * 2019-05-08 2022-02-14 알리고스 테라퓨틱스 인코포레이티드 Thr-베타의 조절제 및 이의 사용 방법
AU2020336272A1 (en) * 2019-08-23 2022-04-14 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
WO2021050945A1 (fr) 2019-09-12 2021-03-18 Terns, Inc. Composés agonistes du récepteur bêta de l'hormone thyroïdienne
WO2021104288A1 (fr) * 2019-11-26 2021-06-03 昆药集团股份有限公司 Composé de 1,2,4-triazine-3,5-dione, son procédé de préparation et son utilisation
WO2021129465A1 (fr) * 2019-12-26 2021-07-01 苏州科睿思制药有限公司 Cristal de resmétirom, son procédé de préparation et ses utilisations
CN113278013B (zh) * 2020-02-20 2022-09-23 昆药集团股份有限公司 2,6-二取代的1,2,4-三嗪-3,5-二酮化合物及其制备方法和应用
US20230257367A1 (en) * 2020-06-02 2023-08-17 Chengdu Kanghong Pharmaceutical Co., Ltd. Novel thyroid hormone beta receptor agonist
WO2021257851A1 (fr) 2020-06-17 2021-12-23 Autobahn Therapeutics, Inc. Thyromimétiques
US12590072B2 (en) 2020-06-17 2026-03-31 Autobahn Therapeutics, Inc. Thyromimetics
WO2022053028A1 (fr) * 2020-09-10 2022-03-17 南京明德新药研发有限公司 Composé de 1,2,4-triazine-3,5-(2h,4h)-dicétone et son utilisation
WO2022052822A1 (fr) * 2020-09-10 2022-03-17 苏州科睿思制药有限公司 Forme cristalline de resmetirom, son procédé de préparation et son utilisation
CA3192169A1 (fr) * 2020-09-17 2022-03-24 Sunshine Lake Pharma Co., Ltd. Compose servant d'agoniste du recepteur ? de l'hormone thyroidienne et utilisations du compose
AU2021373043A1 (en) * 2020-11-06 2023-06-15 Aligos Therapeutics, Inc. Oxindoles and methods of use thereof
JP2023551782A (ja) * 2020-11-06 2023-12-13 アリゴス セラピューティクス，インコーポレーテッド 甲状腺受容体アゴニストとしてのピリダジノン誘導体、及びその使用
CN114591300A (zh) * 2020-12-04 2022-06-07 南京圣和药业股份有限公司 作为THRβ激动剂的杂环化合物及其应用
CN112645936B (zh) * 2020-12-17 2022-03-01 山东第一医科大学(山东省医学科学院) 取代的哒嗪酮类化合物及其用途
CN114685450A (zh) * 2020-12-30 2022-07-01 昆药集团股份有限公司 2-吡啶酮类衍生物及其制备方法和在医药上的应用
CN114907327A (zh) * 2021-02-10 2022-08-16 杭州领业医药科技有限公司 Resmetirom的晶型及其制备方法和用途
PE20240097A1 (es) * 2021-03-03 2024-01-18 Terns Pharmaceuticals Inc Compuestos agonistas beta del receptor de la hormona tiroidea
CA3210814A1 (fr) * 2021-03-04 2022-09-09 Xiaokun SHEN Compose aromatique, son procede de preparation et son utilisation
CN115073429A (zh) * 2021-03-15 2022-09-20 昆药集团股份有限公司 一种1，2，4-三嗪-3，5-二酮类化合物的盐型、晶型及其制备方法
CN117279911B (zh) * 2021-05-21 2025-07-08 深圳微芯生物科技股份有限公司 一种杂环化合物及其应用
WO2023023474A1 (fr) * 2021-08-16 2023-02-23 Senya Pharmaceuticals, Inc. Modulateurs du tr-bêta, compositions pharmaceutiques et applications thérapeutiques
US20250243491A1 (en) 2021-09-01 2025-07-31 Aligos Therapeutics, Inc. Pnpla3-targeting short interfering rna (sirna) molecules and uses thereof
CN118234862A (zh) 2021-09-08 2024-06-21 阿利戈斯治疗公司 经修饰的短干扰核酸分子(siNA)及其用途
TWI910297B (zh) * 2021-12-24 2026-01-01 大陸商廣東東陽光藥業股份有限公司 一種作為甲狀腺激素β受體激動劑的化合物及其用途
CN116354934A (zh) * 2021-12-28 2023-06-30 中国科学院上海药物研究所 一类喹啉类化合物及其制备方法、药物组合物和用途
CN115650928B (zh) * 2022-12-28 2023-03-31 凯思凯旭(上海)医药科技有限公司 一种多环类甲状腺激素β受体激动剂及其用途
WO2024182446A2 (fr) 2023-02-28 2024-09-06 Aligos Therapeutics, Inc. Molécules d'arn interférent court (arnsi) ciblant pnpla3 et leurs utilisations
US20240352464A1 (en) 2023-03-07 2024-10-24 Aligos Therapeutics, Inc. Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof
EP4568664B1 (fr) 2023-04-07 2026-04-01 Terns Pharmaceuticals, Inc. Combinaison comprenant un agoniste thr-beta et un agoniste glp-1r pour son utilisation dans le traitement de l'obésité
CN121358734A (zh) * 2023-06-19 2026-01-16 西威埃医药技术（上海）有限公司 THR-β受体激动剂、其制备方法和其使用方法
WO2025011259A1 (fr) * 2023-07-07 2025-01-16 苏州科睿思制药有限公司 Forme cristalline de resmetirom, son procédé de préparation et son utilisation
CN117327057B (zh) * 2023-08-30 2026-03-03 南京雷正医药科技有限公司 一类作为甲状腺激素受体激动剂的三嗪二酮类化合物及其合成、用途
US20250206725A1 (en) * 2023-12-21 2025-06-26 Aligos Therapeutics, Inc. Modulators of thr-beta and methods of use thereof
WO2025230749A1 (fr) 2024-05-03 2025-11-06 Aligos Therapeutics, Inc. Procédés de préparation de 6-amino-2-[3,5-dichloro-4-[(5-isopropyl-6-oxo -1 h-pyridazin-3-yl) oxy] phényl]-4 h-1, 2, 4-tri-azine-3, 5-dione
WO2025252147A1 (fr) * 2024-06-07 2025-12-11 珠海联邦制药股份有限公司 COMPOSÉ D'AGONISTE DU RÉCEPTEUR DES HORMONES THYROÏDIENNES DE TYPE β ET SON UTILISATION
WO2026050911A1 (fr) * 2024-09-04 2026-03-12 西威埃医药技术（上海）有限公司 FORME CRISTALLINE D'UN AGONISTE SÉLECTIF TR-β, PROCÉDÉ DE PRÉPARATION ET UTILISATION
WO2026067791A1 (fr) 2024-09-30 2026-04-02 Ascletis Pharma (China) Co., Limited Dérivés de 2-phényl-1,2,4-triazine-3,5(2h,4h)-dione en tant qu'agoniste du thr-bêta ou modulateurs pour le traitement de l'obésité
US20260102403A1 (en) * 2024-10-11 2026-04-16 Aligos Therapeutics, Inc. Oral formulations of thr-beta agonist
CN120923503A (zh) * 2025-10-10 2025-11-11 吉斯凯(苏州)制药有限公司 具有杂环结构的化合物、THRβ受体激动剂及用途

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
ES2240017T3 (es) * 1999-09-30 2005-10-16 Pfizer Products Inc. Derivados de 6-azauracilo como ligandos de receptores tiroideos.
GB0015205D0 (en) 2000-06-21 2000-08-09 Karobio Ab Bioisosteric thyroid receptor ligands and method
DK1262177T3 (da) 2001-05-31 2006-11-20 Pfizer Prod Inc Medicinsk brug af thyromimetiske forbindelser til behandling af hårtab og kompositioner
EP1471049A4 (fr) 2002-01-30 2006-08-16 Kissei Pharmaceutical Nouveau ligand de recepteur de l'hormone thyroidienne, preparations medicinales le contenant et leur utilisation
HRP20050089B1 (hr) 2002-07-29 2015-06-19 Rigel Pharmaceuticals Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti
AU2003278544A1 (en) 2002-11-25 2004-06-18 Pfizer Products Inc. Method for promoting nail growth using thyromimetic compounds
DK1919878T3 (da) * 2005-07-21 2010-10-25 Hoffmann La Roche Pyridazinonderivater som thyroidhormonreceptoragonister
US7638531B2 (en) * 2005-12-21 2009-12-29 Schering Corporation Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists
AU2007265940A1 (en) * 2006-06-28 2008-01-03 Sanwa Kagaku Kenkyusho Co., Ltd. Novel 6-5 System Bicyclic Heterocyclic Derivative And Its Pharmaceutical Utility
WO2008104752A1 (fr) * 2007-02-26 2008-09-04 Astrazeneca Ab Dihydropytidones inhibiteurs d'élastase
US8076334B2 (en) 2007-09-20 2011-12-13 Hoffmann-La Roche Inc. Prodrugs of thyroid hormone analogs
RU2527948C2 (ru) 2009-04-20 2014-09-10 Мицубиси Танабе Фарма Корпорейшн Новый агонист бета рецептора тиреоидного гормона
JP5847533B2 (ja) 2010-10-19 2016-01-27 田辺三菱製薬株式会社 新規甲状腺ホルモンβ受容体作動薬
EP2695611B1 (fr) 2012-08-06 2014-10-01 Dr. August Wolff GmbH & Co. KG Arzneimittel Eprotirome pour l'utilisation dans la prévention et/ou le traitement de troubles de cheveux et compositions correspondantes
AR092872A1 (es) 2012-09-17 2015-05-06 Madrigal Pharmaceuticals Inc Metodo para sintetizar analogos de la hormona tiroidea y polimorfos de los mismos
WO2015005901A1 (fr) 2013-07-09 2015-01-15 Bristol-Myers Squibb Company Associations d'inhibiteurs du virus de l'hépatite c
US10303567B2 (en) 2013-08-15 2019-05-28 Entit Software Llc Managing database nodes
GB201318793D0 (en) 2013-10-24 2013-12-11 Plaquetec Ltd Vascular Biomarkers
EA201791258A1 (ru) 2015-01-09 2017-12-29 Джилид Аполло, Ллс Комбинированная терапия с применением ингибитора ацетил-коа-карбоксилазы (acc) для лечения неалкогольной жировой болезни печени
JP2019517523A (ja) 2016-06-03 2019-06-24 ケモセントリックス， インコーポレイテッド 肝線維症を治療する方法
WO2018075650A1 (fr) 2016-10-18 2018-04-26 Madrigal Pharmaceuticals, Inc. Méthodes de traitement de troubles hépatiques ou de troubles lipidiques avec un agoniste thr-bêta
WO2018167103A1 (fr) 2017-03-13 2018-09-20 Genfit Compositions pharmaceutiques pour polythérapie
JP7266531B2 (ja) 2017-04-18 2023-04-28 ジェンフィ エラフィブラノール又はその誘導体と抗ｎａｓｈ剤、抗線維化剤又は抗胆汁うっ滞性剤の組合せ
US10857144B2 (en) 2017-05-16 2020-12-08 Bow River LLC Methods of treatment
CN111183360B (zh) 2017-07-19 2024-10-18 生物辐射欧洲有限公司 同时评估非酒精性脂肪性肝炎和肝纤维化状态的生物标志物组合
WO2019099457A1 (fr) 2017-11-14 2019-05-23 Quixgen, Inc. Composés de benzodioxinone
IL308604B2 (en) 2017-12-06 2025-08-01 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
JP7156722B2 (ja) 2018-01-23 2022-10-19 深▲チェン▼市塔吉瑞生物医薬有限公司 置換ピリダジノン化合物
WO2019178023A1 (fr) 2018-03-12 2019-09-19 Yale University Procédés de traitement ou de prévention du syndrome de détresse respiratoire aiguë
WO2019213611A1 (fr) 2018-05-04 2019-11-07 Cirius Therapeutics, Inc. Analogues de thiazolidinedione pour le traitement de nafld et de maladies métaboliques
CN108727344A (zh) * 2018-05-14 2018-11-02 嘉兴特科罗生物科技有限公司 一种化合物及其合成方法和应用
ES3029158T3 (en) * 2018-06-12 2025-06-23 Xizang Haisco Pharmaceutical Co Ltd Thyroid hormone receptor agonists and uses thereof
WO2019239436A1 (fr) 2018-06-14 2019-12-19 Alma Mater Studiorum - Universita' Di Bologna Fibres électrofilées pour une libération locale d'un médicament anti-inflammatoire et d'un médicament promyélinisant
CN110627773B (zh) 2018-06-22 2021-03-19 海创药业股份有限公司 氘代mgl-3196化合物及其用途
AR115666A1 (es) 2018-07-02 2021-02-10 Madrigal Pharmaceuticals Inc Formas sólidas de 2-(3,5-dicloro-4-((5-isopropil-6-oxo-1,6-dihidropiridazin-3-il)oxi)fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2,4-triazin-6-carbonitrilo
TWI825144B (zh) 2018-08-10 2023-12-11 美商思達利醫藥公司 第二型轉麩醯胺酸酶(tg2)抑制劑
CN112805005A (zh) 2018-08-24 2021-05-14 拓臻股份有限公司 甲状腺素受体β促效剂化合物
TWI884745B (zh) 2018-10-12 2025-05-21 美商拓臻股份有限公司 甲狀腺素受體β促效劑化合物
CA3113373A1 (fr) * 2018-10-12 2020-04-16 InventisBio Co., Ltd. Agonistes du recepteur des hormones thyroidiennes
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
CN113474335B (zh) * 2019-02-21 2024-12-03 南京瑞捷医药科技有限公司 化合物及其作为甲状腺激素受体激动剂的用途
KR20220017917A (ko) * 2019-05-08 2022-02-14 알리고스 테라퓨틱스 인코포레이티드 Thr-베타의 조절제 및 이의 사용 방법
WO2020228577A1 (fr) 2019-05-10 2020-11-19 深圳微芯生物科技股份有限公司 Dérivé de pyridazinone et son utilisation
IT201900006923A1 (it) 2019-05-16 2020-11-16 International Soc For Drug Development S R L Nuovi tiromimetici con uno scaffold bifenilmetano e loro uso
WO2020239076A1 (fr) 2019-05-29 2020-12-03 南京明德新药研发有限公司 DÉRIVÉS DE PYRIDAZINONE CONSTITUANT DES AGONISTES DU RÉCEPTEUR DE LA THYROXINE DE TYPE β ET LEUR UTILISATION
TW202115029A (zh) 2019-07-31 2021-04-16 大陸商深圳微芯生物科技股份有限公司 雜環化合物及其用途
AU2020334943A1 (en) 2019-08-19 2022-03-10 Hepagene Therapeutics (HK) Limited Heterocyclic THR-β receptor agonist compound and preparation method and use therefor
CN112409340B (zh) 2019-08-21 2022-03-18 海创药业股份有限公司 卤素取代的苯醚类化合物及其用途
AU2020336272A1 (en) 2019-08-23 2022-04-14 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
WO2021043185A1 (fr) 2019-09-04 2021-03-11 Sunshine Lake Pharma Co., Ltd. Composé utilisé comme agoniste du récepteur bêta des hormones thyroïdiennes et son utilisation
WO2021050945A1 (fr) 2019-09-12 2021-03-18 Terns, Inc. Composés agonistes du récepteur bêta de l'hormone thyroïdienne
WO2021057791A1 (fr) 2019-09-24 2021-04-01 广东东阳光药业有限公司 Composé chimique en tant qu'agoniste du récepteur bêta de l'hormone thyroïdienne et son utilisation
CN112707892A (zh) 2019-10-24 2021-04-27 苏州泽璟生物制药股份有限公司 哒嗪酮或哒嗪类化合物及其衍生物和药物组合物
WO2021104288A1 (fr) 2019-11-26 2021-06-03 昆药集团股份有限公司 Composé de 1,2,4-triazine-3,5-dione, son procédé de préparation et son utilisation
MX2022008626A (es) 2020-01-13 2022-08-22 Eccogene Shanghai Co Ltd Triazinonas sustituidas como agonistas del receptor de la hormona tiroidea.
US20230183245A1 (en) 2020-04-06 2023-06-15 Basf Se Imidazo-pyrimidone compounds as pesticides

Also Published As

Publication number Publication date
BR112021021718A2 (pt) 2022-01-18
WO2020227549A1 (fr) 2020-11-12
CA3139101A1 (fr) 2020-11-12
PE20220255A1 (es) 2022-02-16
ZA202409114B (en) 2025-06-25
GEP20247637B (en) 2024-06-25
CN114096531A (zh) 2022-02-25
SI3965884T1 (sl) 2025-05-30
DK3965884T3 (da) 2025-03-31
JP2022532706A (ja) 2022-07-19
US11091467B2 (en) 2021-08-17
AU2020267576B2 (en) 2025-03-13
HUE070650T2 (hu) 2025-06-28
EP4523692A3 (fr) 2025-06-04
CN114096531B (zh) 2026-03-10
CO2021015698A2 (es) 2022-01-17
US12180192B2 (en) 2024-12-31
WO2020227549A8 (fr) 2021-05-27
MX2021013472A (es) 2022-01-06
MA55890B1 (fr) 2025-03-28
MD3965884T2 (ro) 2025-05-31
TWI855068B (zh) 2024-09-11
PT3965884T (pt) 2025-03-31
EP3965884A1 (fr) 2022-03-16
JP2025011262A (ja) 2025-01-23
IL287720A (en) 2021-12-01
JP7574223B2 (ja) 2024-10-28
JP7844578B2 (ja) 2026-04-13
RS66686B1 (sr) 2025-05-30
US20210355112A1 (en) 2021-11-18
ES3020290T3 (en) 2025-05-22
PH12021552782A1 (en) 2023-01-16
EP3965884B1 (fr) 2025-01-15
US20250304561A1 (en) 2025-10-02
TW202108569A (zh) 2021-03-01
PL3965884T3 (pl) 2025-05-05
US20200354345A1 (en) 2020-11-12
HRP20250384T1 (hr) 2025-05-23
GEAP202415821A (en) 2024-03-11
AU2020267576A1 (en) 2021-12-09
SG11202111552YA (en) 2021-11-29
FI3965884T3 (fi) 2025-04-02
CL2021002883A1 (es) 2022-10-28
KR20220017917A (ko) 2022-02-14
LT3965884T (lt) 2025-04-10
MY210357A (en) 2025-09-13
EP4523692A2 (fr) 2025-03-19

Similar Documents

Publication Publication Date Title
MA55890A (fr) Modulateurs de thr-beta et leurs procédés d'utilisation
MA56457A (fr) Modulateurs de hsd17b13 et leurs procédés d'utilisation
MA52753A (fr) Anticorps anti-sirpa et leurs procédés d'utilisation
EP3968999A4 (fr) Inhibiteurs de fgfr et leurs procédés d'utilisation
EP3911648A4 (fr) Inhibiteurs de pcsk9 et leurs procédés d'utilisation
EP3930901A4 (fr) Dispositifs micro-fluidiques numériques et leurs procédés d'utilisation
EP3790596A4 (fr) Compositions d'oligonucléotides et leurs procédés d'utilisation
EP3775203A4 (fr) Compositions d'oligonucléotides et leurs procédés d'utilisation
EP3911640A4 (fr) Inhibiteurs de pcsk9 et leurs procédés d'utilisation
EP3810185A4 (fr) Variants d'interleukine-2 et leurs procédés d'utilisation
EP3634430A4 (fr) Agents multibiotiques et procédés d'utilisation de ceux-ci
EP3962479A4 (fr) Inhibiteurs de kcnt1 et procédés d'utilisation
EP3962481A4 (fr) Inhibiteurs de kcnt1 et procédés d'utilisation
MA51837A (fr) Inhibiteurs de l'arginase et leurs procédés d'utilisation
MA55025A (fr) Anticorps anti-trem2 et leurs procédés d'utilisation
EP3893917A4 (fr) Compositions d'il-15 et leurs procédés d'utilisation
EP3846808A4 (fr) Inhibiteurs de papd5 et leurs procédés d'utilisation
EP3941475A4 (fr) Pyridazinones et leurs procédés d'utilisation
MA71645A (fr) Pyridazinones et leurs procédés d'utilisation
EP3731867A4 (fr) Anticorps anti-lrp5/6 et leurs procédés d'utilisation
EP4034605A4 (fr) Compositions de polissage et leurs procédés d'utilisation
EP3688373A4 (fr) Brûleurs et leurs procédés d'utilisation
EP3836971A4 (fr) Conjugués et leurs procédés d'utilisation
MA53328A (fr) Anticorps anti-siglec-5 et leurs procédés d'utilisation
EP4045226A4 (fr) Compositions de polissage et leurs procédés d'utilisation